Phase Ib Trial Evalutes Glofitamab Plus Pola-R-CHP in DLBCL
By Cecilia Brown, Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA - Last Updated: June 5, 2023Michael Dickinson, MBBS, DMedSc, of the Peter MacCallum Cancer Centre, discusses a phase Ib study of glofitamab plus pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Dr. Dickinson and colleagues presented the research at the 2023 American Society of Clinical Oncology Annual Meeting.
In this video, Dr. Dickinson outlines the rationale behind testing the combination in patients with previously untreated DLBCL, the study’s key efficacy and safety findings, and the next steps with the research.
Post Tags:ASCO2023
Advertisement
Related Posts
Karun Neupane, MD, discusses why the meeting was a valuable experience for him as a first-time attendee.
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
Dr. de Lima discusses progress and remaining challenges with allogeneic CAR-T and other cellular therapy products.
The proof-of-concept study showed that noninvasive hemoglobin measurement is “feasible,” but there were several ...
One aim is to evaluate the efficacy of oral decitabine/cedazuridine and magrolimab in intermediate to HR MDS.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.